Study Name:
A randomized phase 3 trial in first-line extensive-stage small-cell lung cancer of BNT327 in combination with chemotherapy
Targeted Disease(s):
Lung Cancer
Purpose of Study:
Advancements in small-cell lung cancer clinical trials are leading to new options for patients with extensive-stage small-cell lung cancer (“ES-SCLC”). This trial is evaluating a new trial drug called BNT327 to learn whether it is safe and helpful for people with this fast-growing cancer. BNT327 could help patients who don't have many choices today. More than 1000 patients have been treated with BNT327 in clinical trials to date. In this trial, researchers are evaluating the safety of BNT327 and whether it works when combined with standard chemotherapy drugs (etoposide and carboplatin). They will compare it to another treatment called atezolizumab when also combined with the same chemotherapy drugs. Atezolizumab is an immunotherapy already approved in multiple countries. The goal is to determine which one works better for patients who have not been treated before for extensive stage small-cell lung cancer.
Study Dates:
February 1, 2025 - September 29, 2028
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
BioNTech
ClinicalTrails.gov Identifier:
NCT06712355
